News | March 17, 2009

De Novo Coronary Lesions May Benefit from New Stent Treatment, Study Shows

March 17, 2009 – Twelve-month data from the ATLANTA Trial shows that the CATANIA Coronary Stent System with NanoThin Polyzene-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.

The CATANIA Stent may be an alternative to both bare metal stents (BMS) and drug-eluting stents (DES). These conclusions were published in the latest issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

Sponsored by CeloNova BioSciences, manufacturer of the CATANIA stent, the ATLANTA Trial is a first-in-man (FIM), prospective, single center study involving 55 patients treated with the CATANIA Stent for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries.

At 12 months, in a reportedly unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis, death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven), with a binary restenosis rate of 6.8 percent. All patients stopped dual anti-platelet therapy after 30 days. The procedural success rate was 100 percent.

Independent laboratories analyzed coronary angiography and intravascular ultrasound data for all patients immediately after stent implantation and at 6-months. Analysis of 19,028 struts using optimal coherence tomography in a subset of 15 randomly selected patients revealed complete endothelialization and 99.5 percent stent strut coverage.

"CeloNova has started a scientific revolution involving the way physicians think about BMS and DES. I can definitely assert that Polyzene-F is innovative, effective in several aspects, unique and striking. The 12-month ATLANTA data indicate that the CATANIA stent with Polyzene-F is truly a new and promising class of stent," said Corrado Tamburino, M.D., Ph.D., FESC, FSCAI, FSICI-GISE, professor of cardiology and chief of the cardiovascular department, Ferrarotto Hospital, Catania, Italy, and lead investigator in the ATLANTA Trial.

The rapid-exchange, cobalt-chromium CATANIA stent is currently available for sale in Europe in 60 sizes, in lengths from 8-38mm and in diameters from 2.0-4.0mm. The CATANIA stent surface has a 35-40 nanometer surface treatment of Polyzene-F, an inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, lubricious, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation.

For more information: www.celonova.com.

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init